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Abstract
The epidermal growth factor receptor (EGFR) family, consisting of four tyrosine kinase receptors, c-erbB1-4, seems
to be influential in gliomagenesis. The aim of this study was to investigate EGFR gene amplification and expression
of c-erbB1-4 receptor proteins in human anaplastic astrocytomas. Formalin-fixed and paraffin-embedded sections
from 31 cases were investigated by standard immunohistochemical procedures for expression of c-erbB1-4 receptor
proteins using commercial antibodies. EGFR gene amplification was studied by fluorescence in situ hybridization
using paraffin-embedded tissues. Two monoclonal antibodies, NCL-EGFR-384 and NCL-EGFR, were used for EGFR
detection and they displayed positive immunoreactivity in 97% and 71%, respectively. For c-erbB2 detection three
monoclonal antibodies, CB11, 3B5, and 5A2, were applied and they displayed positive immunoreactivity in 45%,
100%, and 52%, respectively. Positive immunostaining for c-erbB3 and c-erbB4 was encountered in 97% and 74%,
respectively. The EGFR gene was amplified in 9 out of 31 tumors (29%). After adjusting for age, Karnofsky perfor-
mance status, and extent of surgical resection, Cox multiple regression analysis with overall survival as the depen-
dent variable revealed that c-erbB2 overexpression detected by the monoclonal antibody clone CB11 was a
statistically significant poor prognostic factor (P = 0.004). This study shows the convenience and feasibility of
immunohistochemistry when determining the expression of receptor proteins in tissue sections of human astrocy-
tomas. The synchronous overexpression of c-erbB1-4 proteins in anaplastic astrocytomas supports their role in the
pathogenesis of these tumors. Further, c-erbB2 overexpression seems to predict aggressive behaviour.
Background
Anaplastic astrocytomas constitute 4% of all malignant
nervous system tumors [1]. Patients with anaplastic
astrocytomas face a poor prognosis despite major efforts
to improve radiation, chemotherapy, and surgical proce-
dures. Median survival for patients with anaplastic astro-
cytoma is 3 to 5 years [2]. Age at diagnosis, extent of
surgery and Karnofsky performance score (KPS) are
established prognostic factors in high grade glioma
patients [3].
The astrocytic tumors are prone to progress, and
members of the epidermal growth factor receptor
(EGFR) family have been linked to this malignant trans-
formation. This receptor family consists of four tyrosine
kinase receptors, c-erbB1-4, and seems to be influential
and involved in tumor cell proliferation, differentiation,
cell survival, and angiogenesis [4-9]. Coexpression of
c-erbB1-4 renders the possibility of dimerization of
these receptors, thereby recruiting and enhancing signal
transducing pathways [4,7,10]. Due to overexpression of
the c-erbB1-4 receptor proteins and their location on
the surface of neoplastic astrocytes, they are attractive
candidates for targeted therapy [11-13]. Current strate-
gies include inhibition of the intrinsic kinase activity by
monoclonal antibodies [14-16]. Such treatment, how-
ever, requires reliable detection systems for these recep-
tor proteins in tumor tissue. Immunohistochemistry
appears as the principal mean to detect these receptor
proteins. Although this is a convenient and feasible
technique, different staining results can be achieved due
to varying sensitivity and specificity of commercial
antibodies.
Several studies have to a varying degree shown ampli-
fication of the EGFR (c-erbB1) gene, located on chromo-
some 7, in glioblastoma multiforme [17-24]. EGFR gene
amplification distinguishes small cell glioblastomas from
anaplastic oligodendrogliomas, and it has been shown to
be an indicator for resistance to radiotherapy [25,26].
EGFR gene amplification can now simply be evaluated
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However, there is limited knowledge concerning the
occurrence of EGFR gene amplification and the expres-
sion of erb-receptors in anaplastic astrocytomas [27,28].
This study was an extension of our research on erb
receptor expression in glioblastomas [8,29], and was
designed to investigate the extent of EGFR gene
amplification and overexpression in anaplastic astrocy-
tomas. Further, we wanted to explore the expression
of other members of the EGFR family in anaplastic
astrocytomas and investigate their prognostic
significance.
Patients and methods
All 31 supratentorial human anaplastic astrocytomas
were operated at the Department of Neurosurgery, St.
Olav University Hospital, Trondheim, Norway, and con-
secutively collected in the time period 1998 to 2006.
Craniotomies were performed under general anesthesia,
with the patient’s head resting in a Mayfield frame sys-
tem (OMI, Inc., Cincinnati, OH, USA) attached to a
reference frame for neuronavigation. The preoperative
data was imported into an ultrasound-based navigation
system and used for surgical planning and resection gui-
dance [30]. All patients underwent magnetic resonance
imaging (MRI) a few days before and within 72 hours
after surgery. The extent of tumor resection was deter-
mined by the postoperative MRI scans. Surgical resec-
tion was defined as gross total resection, partial
resection, or biopsy. A chart review was performed to
collect demographic and clinical data that included age,
sex, and symptoms at presentation, tumor localization,
treatment modalities, and postoperative survival. Preo-
perative Karnofsky performance status score was retro-
spectively determined from a routine neurological
examination from patient admittance, one to three days
before surgery.
Expression of c-erbB1-4 receptor proteins was
determined by immunohistochemistry using various
commercial monoclonal antibodies listed in Table 1.
Formalin-fixed and paraffin-embedded sections, 4 μm
thick, with representative tumor tissue, were incubated
with primary antibodies after antigen retrieval by pres-
sure cooking. An automatized histostainer was used for
the immunohistochemcial procedures (Dako Autostai-
ner, Glostrup, Denmark). For visualization of immunor-
eactivity, DAKO EnVision system was used with
diaminobenzidin as chromogene. Sections were counter-
stained with haematoxylin. Positive controls were
included in each staining run.
The immunoreactivity was assessed by means of
intensity and percentage of immunoreactive tumor cells.
Intensity was recorded as 0 (no reaction) to 3 (strong
reaction). Fraction of immunoreactive tumor cells was
recorded as 0 (no positive cells), 1 (<10% positive cells),
2 (10-50% positive cells), or 3 (>50% positive cells).
A staining index was calculated as the product of inten-
sity and fraction of positive tumor cells [8].
EGFR gene copy number was investigated on 4 μm
thick paraffin sections by double FISH using the LSI
EGFR Dual Color Probe- Hyb Set, Vysis no 32-191053
(Abbott Molecular Inc, IL, US). The first probe hybri-
dized with the EGFR gene (chromosomal 7p12 region).
Against the centromeric region a second probe was
used which revealed the number of copies of chromo-
some 7. The sections were deparaffinised using xylene,
rehydrated, and pretreated using DAKO solution kit
(Histology FISH Accessory kit). The probes were added
to the sections, coverslipped, sealed with rubber cement,
and placed in a DAKO Hybridizer. The sections and
probes were codenatured for 5 min at 73°C, followed by
annealing at 37°C over night. After hybridization slides
were washed in 0.4 × SSC (with detergent) at 73°C for
two minutes followed by one minutes in 2 × SSC at
Table 1 erbB antibodies used
Antibody Source Type Clone Reactant Positive control Dilution Incubation time and
temperature
NCL-
EGFR-384
Novocastra, Newcastle-
upon-Tyne, UK
Monoclonal EGFR.25 EGFR (c-erbB1 protein)
(internal domain)
Human skin 1:100 60 min. at room
temperature
NCL-EGFR Novocastra Monoclonal EGFR.113 EGFR (c-erbB1 protein)
(external domain)
Human skin 1:10 60 min. at room
temperature
c-erbB-2 Novocastra Monoclonal CB11 c-erbB2 protein (internal
domain)
SKBR-3 breast
cancer cell line
1:40 60 min. at room
temperature
c-erbB-2 Immunotech, Marseille,
France
Monoclonal 3B5 c-erbB2 protein (internal
domain)
SKBR-3 breast
cancer cell line
Ready to
use
60 min. at room
temperature
c-erbB-2 Novocastra Monoclonal 5A2 c-erbB2 protein (internal
domain)
SKBR-3 breast
cancer cell line
1:50 60 min. at room
temperature
NCL-c-
erbB-3
Novocastra Monoclonal RTJ1 c-erbB-3 protein Normal kidney 1:10 Over night at 4°C
c-erbB-4/
HER4
NeoMarkers (Fremont,
CA, USA)
Monoclonal HFR-1 c-erbB-4 protein Breast carcinoma 1:10 Over night at 4°C
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drating in ethanol three times for 3 min. The slides
were counterstained and embedded with a 4,6-diami-
dino-2-phenylindole/antifade solution (DAKO). FISH
signals for each locus-specific FISH probe were assessed
under a Nikon Eclipse 90i microscope (Nikon, Tokyo,
Japan) using Cytovision software (Applied Imaging,
Newcastle upon Tyne, England) equipped with a triple-
pass filter (DAPI/Green/Orange). The entire area of
tumour tissue was evaluated in each case, and all non-
overlapping nuclei were assessed for orange (marker)
and green (reference) signals by a pathologist (SHT)
blinded to any information about the patients. Using the
criteria given by Vysis Inc., for HER-2/neu FISH, EGFR
signals to chromosome 7 centromere signals of 2 or
greater were considered gene amplification [31].
Statistical analyses were made using SPSS version 16.0
(SPSS Inc., Chicago, IL). Survival time was calculated
from date of surgery to date of death. Multiple Cox
regression analyses were used to study the association
between EGFR receptor protein expression (Staining
Index, continuous variable) and survival, adjusting for
age at diagnosis (continuous variable), Karnofsky perfor-
mance status scores (continuous variable), and extent of
surgical resection (categorical variable; gross total resec-
tion versus partial resection and biopsy). The association
between results from the FISH investigations (categori-
cal variables; positive versus negative) and survival were
studied in the same manner. Two-sided P-values less
than 0.05 were regarded as statistically significant.
The study was approved by the Regional Committee
for Medical Research Ethics, and study protocols
adhered to guidelines by the Helsinki Convention.
Results
Thirty-one consecutive patients (13 women and 18 men;
mean age, 50.2 yr; age range, 28-78 yr) with anaplastic
astrocytomas were included in the study. Clinical fea-
tures of the study group are presented in Table 2. Gross
total tumor resection or partial resection was achieved
in 10 (32%) and 16 (52%) patients, respectively. In
5 (16%) patients only biopsies were obtained. Four
patients had previously undergone surgical resection of
diffuse WHO grade II astrocytomas. Chemotherapy and
radiotherapy were provided in 7 and 24 cases,
respectively.
Immunohistochemical and FISH data are presented in
Table 3. In general, the immunoreactivity was localized
to either the cell membrane or the cytoplasm or both.
The distribution of tumor cells overexpressing erb pro-
teins was both diffuse and dispersed with intensity vary-
ing from weak to strong.
Two monoclonal antibodies were used for EGFR
detection. NCL-EGFR (clone EGFR.113) is reactive
against the external EGFR domain and rendered 22
positive tumors (71%). NCL-EGFR-384 is directed
towards the internal domain, and 30 tumors (97%) were
positive with this antibody.
To determine c-erbB2 expression, three different
monoclonal antibodies were applied. The antibody
clones CB11, 3B5, and 5A2 were all reactive against the
internal domain and displayed positive immunoreactivity
in 45%, 100%, and 52%, respectively (Figure 1A).
C-erbB3 immunoreactivity occurred in 27 out of 31
anaplastic astrocytomas (97%), and c-erbB4 immunor-
eactivity was present in 23 out of 31 cases (74%).
The EGFR gene was amplified in 9 out of 31 tumors
(29%) assessed by FISH (Figure 1B).
Multiple Cox regression analysis with overall survival
as the dependent variable was performed for clinical
disease features withe x p r e s s i o no fc - erbB1-4 and
EGFR gene amplification (Table 4). After adjusting for
age, Karnofsky performance status, and extent of surgi-
cal resection, the Cox analysis revealed that c-erbB2
overexpression detected by the monoclonal antibody
clone CB11 was a statistically significant poor prognos-
tic factor in patients with anaplastic astrocytoma
(P = 0.004). Neither overexpression of EGFR, c-erbB3,
and c-erbB4, nor EGFR gene amplification reached
significance.
Discussion
I nt h i ss t u d yw eh a v ef o u n da b u n d a n tc o - e x p r e s s i o no f
c-erbB1-4 receptor proteins in anaplastic astrocytomas.
Cox multiple regression analysis showed that c-erbB2
expression detected by the monoclonal antibody clone
CB11 was a statistically significant poor prognostic fac-
tor. Additionally, the EGFR gene was amplified in 29%
of the tumors.
T h eo v e r e x p r e s s i o no fE G F Ri na n a p l a s t i ca s t r o c y t o -
mas is in line with our earlier report and other studies
[24,28,32-34]. Interestingly, the antibody reactive against
the cytoplasmic domain unveiled far more immunoreac-
tive tumors than the antibody against the external
domain (97% versus 71%). A similar observation was
made in our recent report on glioblastomas [8]. A possi-
ble explanation might be that the extracellular part of
the EGFR is more vulnerable to fixation and tissue pro-
cessing. It may also be due to proteolytic cleavage and
shedding of EGFR as is described for c-erbB2 [35,36]. In
any case, further studies must be undertaken to decide
which antibody is best suited for standardized EGFR
immunohistochemical detection. Such investigations
require alternative assays for protein expression, such as
protein blotting.
Amplification of the EGFR gene occurs in up to 50%
of human glioblastomas, whereas the reported frequency
in anaplastic astrocytomas varies considerably between
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Different techniques and definitions of gene dosage may
explain these conflicting data. In this regard, FISH ana-
lyses have turned out to be a simple and reliable method
[28,32]. In our series of anaplastic astrocytomas this
approach revealed a relatively high frequency of EGFR
gene amplification with 29% of the tumors exhibiting
this genetic rearrangement. It seems this genetic event
is not solely confined to glioblastomas, and it may be
coupled to the malignant progression of anaplastic
astrocytomas. It remains to be shown whether this gene
amplification is a cause or a consequence of tumor pro-
gression. Nevertheless, it may be involved in the onco-
genesis of both primary and secondary glioblastomas.
Overexpression of EGFR in astrocytomas can also occur
without gene amplification [8,28,32,37,39], suggesting
other mechanisms at transcriptional and translational
levels. An amplified EGFR gene may lead to expression
of mutant EGFR (EGFRvIII) in high grade astrocytomas
[27], providing a possible target for immunotherapy
[41]. Even though there are several studies advocating
the importance of EGFR in the oncogenesis of astrocy-
tomas [5,9], the prognostic role of EGFR overexpression
and EGFR gene amplification is still not fully clarified
[5,8,9,27,31,39,42-46]. Neither EGFR gene amplification
nor EGFR overexpression was associated with survival
in this study. Conflicting prognostic data may be related
to various techniques and small series of tumors studied,
so larger studies are required to explore the prognostic
impact of EGFR.
C-erbB2 is already an established negative prognostic
marker with an associated targeted therapy in human
breast cancer [47]. It has been suggested that c-erbB2 is
a preferred partner for heterodimerization with the
other members of the EGFR family. The physiological
ligand of c-erbB2 has not been identified, and it is
Table 2 Patient characteristics
Case no. Age (years)/Sex Prior brain tumor KPS Resection grade Radiotherapy Postoperative survival (months)
1 57/M No 80 Partial 1.8 Gy × 30 16.6
2 34/F No 80 Partial 1.8 Gy × 30 29.4
3 44/M Grade II astrocytoma 90 Partial No 41.5
4 28/F No 90 GTR 1.8 Gy × 30 55.4
5 57/F No 70 Partial 1.8 Gy × 30 5.6
6 50/M Grade II astrocytoma 80 Partial 1.8 Gy × 30 23.7
7 67/F No 80 Partial 1.8 Gy × 30 12.1
8 39/F No 70 GTR N.D. N.D.
9 53/M No 70 Partial 1.8 Gy × 30 24.6
10 78/F No 50 Biopsy 3.0 Gy × 13 9.8
11 34/F No 80 Partial 1.8 Gy × 30 95.8+
12 42/M No 70 GTR 1.8 Gy × 30 93.6+
13 78/M No 50 Biopsy No 1.9
14 40/M No 70 GTR 1.8 Gy × 30 53.9
15 47/M Grade II astrocytoma 90 GTR No 90+
16 49/M No 50 Biopsy No 0.1
17 64/M No 70 GTR 1.8 Gy × 30 76.1+
18 48/F No 80 GTR 1.8 Gy × 30 8.3
19 57/F No 80 Partial 1.8 Gy × 30 63.8+
20 72/M No 60 Biopsy 1.8 Gy × 30 11.1
21 36/M No 70 Partial 3.0 Gy × 13 11.2
22 56/F No 70 Partial 2.0 Gy × 30 17.9
23 53/F No 80 GTR 2.0 Gy × 30 59.8+
24 44/F No 80 GTR No 59.8+
25 37/M No 80 GTR No 54.6+
26 58/M No 80 Partial 1.8 Gy × 30 28.6
27 32/F No 70 Partial 2.0 Gy × 30 16.2
28 38/M No 80 Partial 2.0 Gy × 30 35.3+
29 71/M No 50 Biopsy 3.0 Gy × 13 10.2
30 49/M No 70 Partial 2.0 Gy × 30 30.6+
31 44/M Grade II astrocytoma 80 Partial 1.8 Gy × 30 39.4+
M = Male, F = Female, KPS = Karnofsky Performance Status, GTR = Gross total resection, N.D. = No data. (+) denotes that the patient is still alive.
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erodimerization in the absence of ligand binding [48]. In
our series of anaplastic astrocytomas, three different
antibodies were applied for detection of the c-erbB2
receptor protein in tumor tissue. They were all reactive
against the internal domain and provided satisfactory
immunostainings. In line with divergent reports on the
presence of this receptor in malignant astrocytomas
[8,21,49-55], the number of immunoreactive tumors
differed considerably between the antibodies used. This
c a np a r t l yb ee x p l a i n e db yt h e application of different
antibodies, subjective assessments of immunostaining,
differences in tissue processing, and small sample series.
Accordingly, the reported prognostic power of this
receptor protein is debatable as well. Even so, reports
including the present study point to an unfavourable
outcome in neuroepithelial tumors with c-erbB-2 over-
expression [51,52,56,57].
Table 3 Immunohistochemical and FISH data
Case no. c-erbB-1
(clone EGFR.25)
(internal
domain)
c-erbB-1
(clone EGFR.113)
(external domain)
c-erbB-2
(clone CB11)
(internal
domain)
c-erbB-2
(clone 3B5)
(internal
domain)
c-erbB-2
(clone 5A2)
(internal
domain)
c-erbB-3 c-erbB-4 EGFR gene
amplification
(FISH)
1 9 9 4 6 6 9 4 Yes
29 1 0 9 3 4 2 N o
36 0 4 3 1 9 0 N o
46 1 1 9 0 0 0 N o
50 0 4 6 2 6 4 N o
6 1 9 1 4 0 4 0 Yes
79 9 0 1 0 0 0 N o
8 6 2 0 6 4 6 4 Yes
99 9 2 6 0 6 6 N o
10 9 9 0 9 1 9 4 Yes
11 4 0 2 6 0 4 4 Yes
12 9 4 0 6 2 9 2 Yes
13 9 2 4 6 1 9 2 No
14 4 0 0 1 0 0 0 No
15 2 1 0 9 1 6 0 No
16 6 0 0 4 0 6 1 No
17 9 2 0 9 4 9 2 No
18 4 1 6 9 1 4 4 No
19 4 0 0 1 0 4 0 Yes
20 6 1 1 6 0 6 1 Yes
21 6 4 1 6 0 4 2 No
22 9 6 2 6 6 4 2 No
23 9 3 0 6 0 1 0 No
24 6 0 0 6 3 6 2 No
25 6 2 1 6 3 9 2 No
26 6 4 6 6 2 4 1 Yes
27 6 0 0 1 0 2 1 No
28 6 1 0 4 0 4 1 No
29 9 6 0 4 0 0 1 No
30 3 0 0 4 0 2 2 No
31 6 1 0 9 3 9 6 No
Median
Staining
Index
61 0 6 1 4 2
No. of
positive
cases/Total
no. of cases
30/31 22/31 14/31 31/31 16/31 27/31 23/31 9/31
Percentage
positivity
97% 71% 45% 100% 52% 97% 74% 29%
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Page 5 of 9Figure 1 (A) Positive immunoreactivity for c-erbB2 (clone CB-11) (40×). (B) FISH analysis showing EGFR gene amplification (Chromosome
7 centromeric probe in green, EGFR probe in red).
Table 4 Results from multiple Cox regression analyses
Variable Hazard ratio 95% Confidence interval P
c-erbB1 (clone EGFR.113) staining index 1.076 0.92 to 1.26 0.37
Karnofsky performance status 0.913 0.85 to 0.98 0.008
Gross total resection 0.196 0.05 to 0.79 0.022
Age 0.998 0.95 to 1.05 0.95
c-erbB1 (clone EGFR.25) staining index 0.991 0.80 to 1.23 0.93
Karnofsky performance status 0.912 0.85 to 0.98 0.009
Gross total resection 0.199 0.05 to 0.82 0.026
Age 1.007 0.96 to 1.06 0.79
c-erbB2 (clone CB11) staining index 1.642 1.17 to 2.30 0.004
Karnofsky performance status 0.854 0.78 to 0.94 0.001
Gross total resection 0.324 0.08 to 1.38 0.13
Age 0.973 0.92 to 1.03 0.36
c-erbB2 (clone 5A2) staining index 1.036 0.79 to 1.35 0.80
Karnofsky performance status 0.910 0.85 to 0.98 0.009
Gross total resection 0.186 0.05 to 0.78 0.021
Age 1.005 0.96 to 1.06 0.85
c-erbB2 (clone 3B5) staining index 1.018 0.84 to 1.23 0.86
Karnofsky performance status 0.912 0.85 to 0.98 0.009
Gross total resection 0.190 0.05 to 0.77 0.020
Age 1.006 0.96 to 1.06 0.81
c-erbB3 (clone RTJ1) staining index 0.975 0.83 to 1.15 0.76
Karnofsky performance status 0.914 0.85 to 0.98 0.010
Gross total resection 0.204 0.05 to 0.81 0.024
Age 1.008 0.96 to 1.06 0.74
c-erbB4 (clone HFR-1) staining index 0.902 0.68 to 1.20 0.48
Karnofsky performance status 0.907 0.85 to 0.97 0.005
Gross total resection 0.178 0.05 to 0.72 0.015
Age 1.003 0.96 to 1.05 0.90
EGFR gene amplification 0.689 0.23 to 2.11 0.51
Karnofsky performance status 0.919 0.86 to 0.99 0.021
Gross total resection 0.175 0.04 to 0.73 0.017
Age 1.013 0.96 to 1.07 0.63
Multiple Cox regression analyses were used to study the association between c-erbB1-4 expression and survival, adjusting for age at diagnosis, Karnofsky
performance status scores, and extent of surgical resection. The association between EGFR amplification and survival was studied in the same manner.
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requisite for overexpression in gliomas [49,58] and FISH
analyses are therefore superfluous in this context.
The overexpression of c-erbB3 and c-erbB4 is in
accordance with our previous study on glioblastomas as
well as with others [8,21,54,59,60]. These findings sug-
gest involvement of these two receptor proteins in the
oncogenesis of astrocytomas. However, no association
with survival was detected in our study. By forming het-
erodimers with other members of the EGFR family, c-
erbB3 channels erbB signaling through the PI3K/Akt
pathway which in turn promotes tumor growth and pro-
gression. This phenomenon may limit the impact of
exclusively targeting EGFR and c-erbB2 proteins, and
may explain the acquired resistance to anticancer drugs
that inhibit receptor tyrosine kinases [61]. The close
integration of different erbB signaling systems and their
interactions with other tyrosine kinases such as IGF1-R
and c-met, suggest that the members of the EGFR
family should be dealt with as a group rather than
individually.
T h er o l eo fc - erbB4 in tumorigenesis has not been
fully established. Cooperation between erb proteins may
also be of clinical relevance as mutual expression of c-
erbB2 and c-erbB4 serves as an independent negative
prognostic factor in childhood medulloblastoma [56]. A
unique feature for c-erbB4 is that pre-mRNA undergoes
alternative splicing, generating structurally distinct iso-
forms. The c-erbB4 isoforms have different signalling
capabilities and may lead to diverse cellular responses.
This might explain the inconsistent reports evaluating
the role of c-erbB4 in breast cancer [62].
This retrospective study has limitations typical of
immunohistochemical approaches, including limited
technical reproducibility and subjective interpretation.
In summary, this study shows the convenience and fea-
sibility of immunohistochemistry when determining the
expression of receptor proteins in tumor tissue. Our
findings indicate that c-erbB2 overexpression predicts
aggressive behaviour in human anaplastic astrocytomas.
The coexpression of members of the EGFR family
underlines their role in the oncogenesis of anaplastic
astrocytomas and supports their promising clinical rele-
vance in regard to prognosis, diagnosis, and therapy.
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